Shield Therapeutics plc (LON:STX – Get Free Report) was down 3.4% on Wednesday . The company traded as low as GBX 2.80 ($0.04) and last traded at GBX 2.80 ($0.04). Approximately 2,343,094 shares were traded during mid-day trading, a decline of 48% from the average daily volume of 4,502,179 shares. The stock had previously closed at GBX 2.90 ($0.04).
Shield Therapeutics Trading Down 2.4 %
The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The company has a market capitalization of £22.52 million, a P/E ratio of -72.50 and a beta of 1.42. The firm has a fifty day moving average price of GBX 3.76 and a 200-day moving average price of GBX 2.99.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More
- Five stocks we like better than Shield Therapeutics
- How to Capture the Benefits of Dividend Increases
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- Top Stocks Investing in 5G Technology
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
